

To Whom it may concern

June 20, 2024

Ohara Pharmaceutical Co., Ltd.

**Additional Investment in Revital Healthcare (EPZ) Limited**

**Ohara Pharmaceutical Co., Ltd. Announces Increased Production Capacity for  
Essential Medical Device Supplies in Africa & beyond**

Ohara Pharmaceutical Co., Ltd. (President and CEO: Seiji Ohara, hereinafter referred to as "the Company") has made an additional investment in Revital Healthcare (EPZ) Limited (President: Rajni Vora, hereinafter referred to as "Revital"), the largest manufacturer of medical devices in sub-Saharan Africa.

**1. Background and Purpose**

The Company is committed to supporting the growth of regionally established healthcare companies in Africa to address various social issues through the dissemination of quality healthcare services and the improvement of quality of life (QOL).

In 2021, the Company partnered with the Africa Healthcare Fund (AHF-1), operated by AAIC Investment Pte. Ltd. (headquarters: Singapore, hereinafter referred to as "AAIC"), to participate in the recapitalization of Revital. In the same year, the Bill & Melinda Gates Foundation contributed for Revital by providing a grant of USD 4 million to innovate Africa's first patented syringe, making Revital one of only five companies worldwide to achieve this milestone.

This year, we have decided to make an additional investment in Revital's new recapitalization plan to expand the new manufacturing facilities for Rapid Diagnostic test kits (RDTs) and other medical products launched in May 2024.

Revital, headquartered in Kilifi, Kenya, is a leading African manufacturer producing medical devices such as syringes and test kits. Following our initial investment in 2021, Revital expanded its facilities, increased production capacities for Re-Use Preventing

syringes, and began manufacturing RDTs. During the COVID-19 pandemic, Revital exported over 70 million vaccine syringes to 20+ countries globally, including India.

Despite these advancements, Africa's medical device sector remains heavily reliant on imports, including test kits. To address this, Revital has invested in equipment to manufacture RDTs for HIV, Malaria, and other infectious diseases. These efforts meet the requirements of the Kenyan government and international non-profit organizations, including the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF). The new facility launched in May 2024 significantly increases supply capacity to 20 million kits per month, focusing on communicable diseases such as HIV, malaria, and hepatitis. There are also plans to expand to non-communicable diseases and livestock testing. Our additional investment will further enhance production capabilities.

Through this investment, we expect Revital to expand its capacity to supply quality medical devices that meet regional needs and contribute to improving health standards in African countries beyond Kenya.

## **2. The Business of Revital**

Revital is the largest manufacturer of medical devices in sub-Saharan Africa, based in Mombasa, Kenya. Its products have received numerous esteemed international certifications, including WHO Performance, Quality and Safety (PQS) certification. Revital collaborates with the United States Agency for International Development (USAID), the Bill & Melinda Gates Foundation, and UNICEF to provide medical devices to over 40 countries worldwide, striving to improve health standards in Africa. Notably, during the COVID-19 pandemic, Revital exported vaccine syringes globally, including to emerging Asian countries.

On May 7, 2024, with support from USAID, Revital began producing RDTs for sub-Saharan Africa. The new facility can manufacture 20 million test kits per month for various diseases, including HIV, malaria, and hepatitis B/C.

Revital is constructing a new plant near its headquarters to expand its product portfolio to include infusion bags. In January 2024, a strategic alliance with Mitsui O.S.K. Lines, Ltd. and MOL Logistics Co., Ltd. was signed to plan the construction of a distribution center for medical devices and medicines in the Free Trade Area near New Mombasa Port and the

International Airport. Revital will begin construction of Africa's largest healthcare kit assembly and pharmaceutical re-packaging units.

#### **Revital Healthcare (EPZ) Ltd**

- **Location:** Mombasa, Kenya
- **Representative:** Rajni Vora
- **Established:** 2007
- **Website:** [Revital Healthcare](#)
- **Business Activities:** Manufacturing over 45 medical devices, including syringes (reuse-preventing, fixed-dose, and conventional), RDTs (e.g., coronavirus, HIV, malaria, dengue fever, syphilis), oxygen delivery systems (bCPAP), PPE kits, surgical masks, and blood transfusion kits. Certified by international organizations such as WHO-PQS, ISO 13485, ISO 14001, ISO 9001, CE-TUV, WHO-GMP, US-FDA-EUA, Health Canada, NAFDAQ, MHRA, TGA. Products recommended by UNICEF, WHO, and CHMP.

#### **Ohara Pharmaceutical Co., Ltd**

- **Location:** Shiga, Japan
- **Representative:** Seiji Ohara
- **Established:** 1964
- **Website:** [Ohara Pharmaceutical](#)
- **Business Activities:** Discovery and manufacture of orphan and generic drugs. Focuses on developing new drugs in core therapeutic areas such as child cancer, hematologic cancer, CNS, and the development, manufacturing, and marketing of generic drugs. Aims to provide comprehensive healthcare solutions by innovating in treatment, prevention, diagnosis, and aftercare.

Contact information

Ohara Pharmaceutical Co., Ltd.

Representatives: Iyo

TEL: 03-6740-7701

FAX: 03-6740-7702